Citations

Mayo Clinic

Clear

9374 citation(s) found for "Ly, Thomas".

Role of Transient Receptor Potential C3 in TNF-α–Enhanced Calcium Influx in Human Airway Myocytes
White, Thomas A. , Xue, Ailing, Chini, Eduardo N. , Sieck, Gary C. , Wylam, Mark E. , Thompson, Michael A. , Sieck, Gary

American Journal of Respiratory Cell and Molecular Biology | March 30, 2006 | Volume: 35 | Issue: 2 | Pages: 243-251

10.1165/rcmb.2006-0003oc | PMID 16574942 Get It

Abstract Previous studies have suggested that the proinflammatory cytokine, TNF-α, contributes to airway hyperresponsivness by altering airway smooth muscle (ASM) Ca2+ responses to agonist stimulation. The present study examined the effects of TNF-α on Ca2+ influx pathways in cultured human ASM cells (HASMCs). Proteins encoded by the transient receptor potential (TRP) gene family function as channels through which receptor-operated and store-operated Ca2+ entry (SOCE) occur. In the present study, the presence of TRPC1, TRPC3, TRPC4, TRPC5, and TRPC6 mRNA and protein expression was confirmed in cultured HASMCs using RT-PCR and Western blot analysis. TNF-α treatment significantly increased TRPC3 mRNA and protein levels in HASMCs as well as SOCE. TNF-α treatment also increased both the peak and plateau intracellular Ca2+ concentration responses in HASMCs elicited by acetylcholine and bradykinin. The effects of TNF-α treatment on SOCE and agonist-induced intracellular Ca2+ concentration responses were attenuated using small interfering RNA transfection, which knocked down TRPC3 expression. Thus, in inflammatory airway diseases, TNF-α treatment may result in increased myocyte activation due to altered Ca2+ influx pathways. These results suggest that TRPC3 may be an important therapeutic target in inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease.
Noncontact modal analysis of a pipe organ reed using airborne ultrasound stimulated vibrometry
Huber, Thomas M. , Fatemi, Mostafa , Kinnick, Randy, Greenleaf, James F. , Fatemi, Mostafa

The Journal of the Acoustical Society of America | March 29, 2006 | Volume: 119 | Issue: 4 | Pages: 2476-2482

10.1121/1.2171516 | PMID 16642860 Get It

The goal of this study was to excite and measure, in a noncontact manner, the vibrational modes of the reed from a reed organ pipe. To perform ultrasound stimulated excitation, the audio-range difference frequency between a pair of ultrasound beams produced a radiation force that induced vibrations. The resulting vibrational deflection shapes were measured with a scanning laser vibrometer. The resonances of any relatively small object can be studied in air using this technique. For a 36mm×6mm brass reed, displacements and velocities in excess of 5μm and 4mm∕s could be imparted at the fundamental frequency of 145Hz. Using the same ultrasound transducer, excitation across the entire range of audio frequencies was obtained. Since the beam was focused on the reed, ultrasound stimulated excitation eliminated background effects observed during mechanical shaker excitation, such as vibrations of clamps and supports. The results obtained using single, dual and confocal ultrasound transducers in AM and two-beam modes, along with results obtained using a mechanical shaker and audio excitation using a speaker are discussed.
In Situ Single-Molecule Imaging with Attoliter Detection Using Objective Total Internal Reflection Confocal Microscopy
Ajtai, Katalin , Borejdo, Julian , Burghardt, Thomas P.

Biochemistry | March 28, 2006 | Volume: 45 | Issue: 13 | Pages: 4058-4068

10.1021/bi052097d | PMID 16566579 Get It

Dietary Carotenoids and Risk of Lung Cancer in a Pooled Analysis of Seven Cohort Studies
Männistö, Satu , Smith‐Warner, Stephanie A. , Anderson, Kristin E. , Brandt, Piet A. van den , Cerhan, James R. , Colditz, Graham A. , Feskanich, Diane , Freudenheim, Jo L. , Giovannucci, Edward L. , Goldbohm, R. Alexandra, Graham, Saxon, Miller, Anthony B. , Rohan, Thomas E. , Virtamo, Jarmo, Spiegelman, Donna , Albanes, Demetrius , Willett, Walter C. , Hunter, David J. , Cerhan, James R , Colditz, Graham A

Cancer Epidemiology, Biomarkers & Prevention | March 22, 2006 | Volume: 13 | Issue: 1 | Pages: 40-48

10.1158/1055-9965.epi-038-3 | PMID 14744731 Get It

Abstract Intervention trials with supplemental β-carotene have observed either no effect or a harmful effect on lung cancer risk. Because food composition databases for specific carotenoids have only become available recently, epidemiological evidence relating usual dietary levels of these carotenoids with lung cancer risk is limited. We analyzed the association between lung cancer risk and intakes of specific carotenoids using the primary data from seven cohort studies in North America and Europe. Carotenoid intakes were estimated from dietary questionnaires administered at baseline in each study. We calculated study-specific multivariate relative risks (RRs) and combined these using a random-effects model. The multivariate models included smoking history and other potential risk factors. During follow-up of up to 7–16 years across studies, 3,155 incident lung cancer cases were diagnosed among 399,765 participants. β-Carotene intake was not associated with lung cancer risk (pooled multivariate RR = 0.98; 95% confidence interval, 0.87–1.11; highest versus lowest quintile). The RRs for α-carotene, lutein/zeaxanthin, and lycopene were also close to unity. β-Cryptoxanthin intake was inversely associated with lung cancer risk (RR = 0.76; 95% confidence interval, 0.67–0.86; highest versus lowest quintile). These results did not change after adjustment for intakes of vitamin C (with or without supplements), folate (with or without supplements), and other carotenoids and multivitamin use. The associations generally were similar among never, past, or current smokers and by histological type. Although smoking is the strongest risk factor for lung cancer, greater intake of foods high in β-cryptoxanthin, such as citrus fruit, may modestly lower the risk.
Preventive Health Behaviors and Familial Breast Cancer
Madlensky, Lisa , Vierkant, Robert A. , Vachon, Celine M. , Cerhan, James R. , Vadaparampil, Susan T. , Sellers, Thomas A. , Vachon, Celine M. , Pankratz, V. Shane , Cerhan, James R , Vierkant, Robert A

Cancer Epidemiology, Biomarkers & Prevention | March 21, 2006 | Volume: 14 | Issue: 10 | Pages: 2340-2345

10.1158/1055-9965.epi-05-0254 | PMID 16214914 Get It

Abstract Aim: To examine medical and lifestyle preventive behaviors among women with varying levels of familial breast cancer risk. Methods: Using cross-sectional data from the Minnesota Breast Cancer Family Study, a historical cohort of 426 families, we compared medical (mammography adherence, antiestrogen use, and prophylactic surgery) and lifestyle (physical activity, smoking, alcohol, and diet) behaviors across three groups of cancer-free women ages 18 to 95 defined by their family history of breast cancer. Family history was classified as high-risk, moderate-risk, or average to low-risk depending on the number and degree of relationship of family members with breast cancer. Results: After adjusting for age and education, high-risk women were twice as likely to have ever used an antiestrogenic agent (9.0% versus 4.6% among moderate-risk and 4.1% among average to low-risk; P = 0.002). Among women ages <40, the high-risk group were more likely to have ever had a mammogram (82% versus 47% among moderate-risk and 35% among average to low-risk; P < 0.001). Average to low-risk women were the least likely to be current smokers and high-risk women may consume slightly fewer fruits and vegetables compared with the other groups, but there were no other differences in lifestyle behaviors, including physical activity and alcohol use. Conclusions: Women with strong family histories of breast cancer are more likely to undertake medical but not lifestyle preventive behaviors.
Estrogen Bioactivation, Genetic Polymorphisms, and Ovarian Cancer
Sellers, Thomas A. , Schildkraut, Joellen M. , Pankratz, V. Shane , Vierkant, Robert A. , Fredericksen, Zachary S., Cunningham, Julie M. , Taylor, William, Liebow, Mark , McPherson, Carol, Hartmann, Lynn C. , Adjei, Araba A., Olson, Janet E. , Pal, Tuya , Vierkant, Robert A

Cancer Epidemiology, Biomarkers & Prevention | March 21, 2006 | Volume: 14 | Issue: 11 | Pages: 2536-2543

10.1158/1055-9965.epi-05-0142 | PMID 16284375 Get It

Abstract Recent experimental evidence has shown that catechol estrogens can be activated through metabolism to form depurinating DNA adducts and thereby initiate cancer. Limited data are available regarding this pathway in epithelial ovarian cancer. We conducted a case-control study of 503 incident epithelial ovarian cancer cases at the Mayo Clinic in Rochester, MN, and Jacksonville, FL, and a 48-county region in North Carolina. Six hundred nine cancer-free controls were frequency matched to the cases on age, race, and residence. After an interview to obtain data on risk factors, a sample of blood was collected for DNA isolation. Subjects were genotyped for seven common single nucleotide polymorphisms in four genes involved in catechol estrogen formation (CYP1A1 and CYP1B1) or conjugation (COMT and SULT1A1). Data were analyzed using logistic regression, stratified by race, and with adjustment for design factors and potential confounders. None of the individual genotypes were significantly associated with ovarian cancer risk. However, an oligogenic model that considered the joint effects of the four candidate genes provided evidence for an association between combinations of these genes and ovarian cancer status (P = 0.015). Although preliminary, this study provides some support for the hypothesis that low-penetrance susceptibility alleles may influence risk of epithelial ovarian cancer.
Cloning and Characterization of CYP51 from Mycobacterium avium
Pietila, Michael P., Vohra, Pawan K., Sanyal, Bharati, Wengenack, Nancy L. , Raghavakaimal, Sreekumar, Thomas, Charles F.

American Journal of Respiratory Cell and Molecular Biology | March 16, 2006 | Volume: 35 | Issue: 2 | Pages: 236-242

10.1165/rcmb.2005-0398oc | PMID 16543605 Get It

Abstract Mycobacterium avium complex (MAC) causes chronic lung disease in immunocompetent people and disseminated infection in patients with AIDS. MAC is intrinsically resistant to many conventional antimycobacterial agents, it develops drug resistance rapidly to macrolide antibiotics, and patients with MAC infection experience frequent relapses or the inability to completely eradicate the infection with current treatment. Treatment regimens are prolonged and complicated by drug toxicity or intolerances. We sought to identify biochemical pathways in MAC that can serve as targets for novel antimycobacterial treatment. The cytochrome P450 enzyme, CYP51, catalyzes an essential early step in sterol metabolism, removing a methyl group from lanosterol in animals and fungi, or from obtusifoliol in plants. Azoles inhibit CYP51 function, leading to an accumulation of methylated sterol precursors. This perturbation of normal sterol metabolism compromises cell membrane integrity, resulting in growth inhibition or cell death. We have cloned and characterized a CYP51 from MAC that functions as a lanosterol 14α-demethylase. We show the direct interactions of azoles with purified MAC-CYP51 by absorbance and electron paramagnetic resonance spectroscopy, and determine the minimum inhibitory concentrations (MICs) of econazole, ketoconazole, itraconazole, fluconazole, and voriconazole against MAC. Furthermore, we demonstrate that econazole has a MIC of 4 μg/ml and a minimum bacteriocidal concentration of 4 μg/ml, whereas ketoconazole has a MIC of 8 μg/ml and a minimum bacteriocidal concentration of 16 μg/ml. Itraconazole, voriconazole, and fluconazole did not inhibit MAC growth to any significant extent.
Prospective Study of Survival Outcomes in Non-Hodgkin's Lymphoma Patients With Rheumatoid Arthritis
Endo, Justin , Puumala, Susan E. , Aoun, Patricia, Black, Natalie A., O’Dell, James R., Stoner, Julie A., Boilesen, Eugene, Bast, Martin, Bergman, Debra, Ristow, Kay M., Ooi, Melissa , Mikuls, Ted R. , Armitage, Jamés O. , Habermann, Thomas M.

Journal of Clinical Oncology | March 7, 2006 | Volume: 24 | Issue: 10 | Pages: 1597-1602

10.1200/jco.2005.04.6227 | PMID 16520462 Get It

Purpose Although preliminary studies suggest that non-Hodgkin's lymphoma (NHL) complicating rheumatoid arthritis (RA) may be a clinically distinct entity compared with that occurring in the general population, studies examining the impact of antecedent RA on survival are limited. In this prospective study, we examined the association of RA with survival in patients with NHL. Patients and Methods Using two large lymphoma registries, we identified patients with evidence of RA preceding NHL. Survival in RA patients was compared with that of controls using proportional hazards regression, adjusting for the effects of age, sex, lymphoma diagnosis-to-treatment lag time, calendar year, International Prognostic Index score, and NHL grade. Results The frequency of NHL subtypes was similar in RA patients (n = 65) and controls (n = 1,530). Compared with controls, RA patients with NHL had similar overall survival (hazard ratio [HR] = 0.95; 95% CI, 0.70 to 1.30) but were at lower risk of lymphoma progression or relapse (HR = 0.41; 95% CI, 0.25 to 0.68) or death related to lymphoma or its treatment (HR = 0.60; 95% CI, 0.37 to 0.98), but were more than twice as likely to die from causes unrelated to lymphoma (HR = 2.16; 95% CI, 1.33 to 3.50). Conclusion RA is associated with improved NHL-related outcomes, including a 40% reduced risk of death occurring as a result of lymphoma or its treatment and approximately a 60% lower risk of lymphoma relapse or progression compared with non-RA controls. However, the survival advantage gained in RA from the acquisition of lymphomas with favorable prognoses is negated through an increased mortality from other comorbid conditions.
Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients With Cancer
Steensma, David P. , Molina, R, Sloan, Jeff A. , Nikcevich, Daniel A., Schaefer, Paul, Rowland, Kendrith M. , Dentchev, Todor, Novotny, Paul J. , Tschetter, Loren K., Hogan, Thomas F., Law, Amy , Loprinzi, Charles L. , Alberts, Steven R. , Steensma, David P

Journal of Clinical Oncology | February 28, 2006 | Volume: 24 | Issue: 7 | Pages: 1079-1089

10.1200/jco.2005.02.7276 | PMID 16505427 Get It

Purpose To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia. Patients and Methods Eligible patients were randomly assigned at enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously (SC), followed by either standard weekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120K arm) SC every 3 weeks for 18 additional weeks. Results Three hundred sixty-five patients were enrolled. One hundred eighty-three patients were assigned to the 40K arm, and 182 were assigned to the 120K arm. There was no difference in the proportion of patients requiring transfusions during the study (23% in 40K arm and 18% in 120K arm, P = .22) or specifically during the maintenance phase (13% in 40K arm v 15% in 120K arm, P = .58). Patients randomly assigned to the 40K arm were more likely to have a ≥ 2 or ≥ 3 g/dL hemoglobin (Hb) increment, were more likely to have a drug dose held because of high Hb, and had higher mean end-of-study Hb levels. Toxicities, including thromboembolism, and overall survival were similar. Patients in the 40K arm had a higher global quality of life (QOL) at baseline for unclear reasons, whereas patients in the 120K arm had a greater global QOL improvement during the study, so end-of-study QOL was equivalent. Conclusion After three weekly doses of epoetin alfa 40,000 U, a dose of 120,000 U can be administered safely once every 3 weeks without increasing transfusion needs or sacrificing QOL. The Hb increment is somewhat greater with continued weekly epoetin alfa. Lack of blinding as a result of different treatment schedules may have confounded results.
Primary Squamous Cell Carcinoma of the Thyroid: Report of Ten Cases
Booya, Fargol, Sebo, Thomas J., Kasperbauer, Jan L. , Fatourechi, Vahab

Thyroid | February 17, 2006 | Volume: 16 | Issue: 1 | Pages: 89-93

10.1089/thy.2006.16.89 | PMID 16487020 Get It